BISOPROLOL IN THE TREATMENT OF CHRONIC HEART FAILURE
- Authors: Ogarkov M.Y.1, Kovaleva Y.V.1, Mulerova T.A2
-
Affiliations:
- SBEI FPE "Novokuznetsk State Institute of Advanced Training of Physicians" of RMH
- FSBIS "Scientific Research Institute of Complex Problems of Cardiovascular Diseases"
- Issue: No 13 (2016)
- Pages: 91-95
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289197
- ID: 289197
Cite item
Abstract
Beta-blockers, together with angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists, and a number of other groups of drugs used in certain clinical situations, make the maximum contribution to the optimization of prognosis in chronic heart failure (CHF). High-selective amphophilous drug bisoprolol was the first representative of the ß-blockers with proven positive effect on the prognosis of heart failure according to the results of randomized multicenter trial. CIBIS Research Program has demonstrated the ability of the bisoprolol to reduce mortality and rate of hospitalizations in chronic heart failure of various severity, regardless of the etiology of the disease, gender and age of the patient.
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
M. Yu Ogarkov
SBEI FPE "Novokuznetsk State Institute of Advanced Training of Physicians" of RMH
Email: ogarmu@kemcardio.ru
MD, Prof., Head of the Department of Cardiology Novokuznetsk
Yu. V. Kovaleva
SBEI FPE "Novokuznetsk State Institute of Advanced Training of Physicians" of RMHNovokuznetsk
T. A Mulerova
FSBIS "Scientific Research Institute of Complex Problems of Cardiovascular Diseases"Kemerovo
References
- Беленков Ю.Н., Фомин И.В., Мареев В.Ю. и др. Первые результаты Российского эпидемиологического исследования по ХСН. Сердечная недостаточность. 2003;1(4): 26-30.
- Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Сердечная недостаточность. 2006;1(7):112-15.
- Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (III пересмотр). М., 2009.
- Даниелян М.О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения). Дисс. канд. мед. наук. М, 2001. 24 с.
- Фомин И.В. Артериальная гипертония в Российской Федерации - последние 10 лет. Что дальше? Сердце. 2007;3(6):1-6.
- Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф.Т. и соавт.]. М., 2010. С. 7-77.
- Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013;7(14):379-472.
- Consensus recommendations for the management of chronic heart failure. Am. J. Cardiol. 1999;83(suppl. 2A):A1-38.
- Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-56.
- Waagstein F., Hjalmarsson A., Varnauskas E., Waiientin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. 1975;37:1022-26.Francis G.S., Cohn J.N., Johnson G., Rector T.S., Goldman S., Simon A. Plasma norepinephrine, rennin activity and congestive heart failure: relations to survival and the effects of therapy in V-HeFT- II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI40-48.
- MERIT-HF Study Group. Effects of metopro lol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
- Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001;344:1651-58.
- Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A, Dumitrascu D., Ferrari R, Lechat P, Soler-Soler J., Tavazzi L., Spinarova L., Toman J., Böhm M., Anker S.D., Thompson S.G., Poole-Wilson P.A.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005;26:215-25.
- Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am. J. Cardiol. 1991;68(1):61-4.
- Dorow P., Bethge H., Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur. J. Clin. Pharmacol. 1986;31(2):143-47.
- Broekman C.P., Yaensel S.M., Van de Ven L.L., Slob A.K. Bisoprolol and hypertension; effects on sexual function in men. J. Sex Marital. Ther. 1992;18(4):325-31.
- Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long-term treatment of essential hypertension. Cardiovasc. Drugs Ther. 1993;7(Suppl 2):424.
- Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non-insulindependent diabetics. J. Cardiovasc. Pharmacol. 1986;8(Suppl 11):S96-99.
- Buhler F.R., Berglund G., Anderson O.K., Brunner H.R., Scherrer U., van Brummelen P., Distler A., Philipp T., Fogari R., Mimran A., et al. Double-blind of the car-dioselective betablockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J. Cardiovasc. Pharmacol. 1986; 8(Suppl 11):122-27.
- Haasis R., Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur. Heart J. 1987;8(Suppl M): 103-13.
- Goose P., Roudaut R., Herrero G., Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J. Cardiovasc. Pharmacol. 1990;16(Suppl 5):145-50.
- Wai B., Kearney L.G.,Hare D.L., Ord M.,Burrell L.M., Srivastava P.M. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc. Diabetol. 2012;11(1):14.
- A randomized trial of beta-blockade in heart fail ure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994; 90:1765-73.
- Schadlich P.K., Paschen B., Brecht J.G. Economic evaluation of the cardiac insufficiency bisoprolol study for the Federal Republic of Germany. Pharmacoeconomics. 1998;13(1 Pt 2): 147-55.
- Levy P., Lechat P., Leizorovicz A., Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiovasc. Drugs Ther. 1998;12:301-5.
- Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). The CIBIS II Scientific Committee. Fundam. Clin. Pharmacokin. 1997;11:138-42.
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
- Willenheimer R., van Veldhuisen D.J., Silke B., Erdmann E., Follath F., Krum H., Ponikowski P., Skene A., van de Ven L., Verkenne P., Lechat P. CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-35.
- Düngen H.D., Apostolovic S., Inkrot S., Tahirovic E., Töpper A., Mehrhof F., Prettin C., Putnikovic B., Neskovic A.N., Krotin M., Sakac D., Lainscak M., Edelmann F., Wachter R., Rau T., Eschenhagen T., Doehner W., Anker S.D., Waagstein F., Herrmann-Lingen C., Gelbrich G., Dietz R.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur. J. Heart Fail. 2011; 13(6):670-80.
Supplementary files
![](/img/style/loading.gif)